Toxoid Vaccination Against Bacterial Infection Using Cell Membrane-Coated Nanoparticles

Overview

Journal Bioconjug Chem

Publisher American Chemical Society

Specialty Biochemistry

Date 2017 Dec 15

PMID 29241006

Citations 28

Authors

Pavimol Angsantikul

Ronnie H Fang

Liangfang Zhang

Affiliations

Soon will be listed here.

Abstract

As nanoparticles exhibit unique properties attractive for vaccine development, they have been progressively implemented as antigen delivery platforms and immune potentiators. Recently, cell membrane-coated nanoparticles have provided a novel approach for intercepting and neutralizing bacterial toxins by leveraging their natural affinity to cellular membranes. Such toxin-nanoparticle assemblies, termed nanotoxoids, allow rapid loading of different types of toxins and have been investigated for their ability to effectively confer protection against bacterial infection. This topical review will cover the current progress in antibacterial vaccine nanoformulations and highlight the nanotoxoid platform as a novel class of nanoparticulate vaccine. We aim to provide insights into the potential of nanotoxoids as a platform that is facile to implement and can be broadly applied to help address the rising threat of super pathogens.

Citing Articles

Unveiling the promise: Exosomes as game-changers in anti-infective therapy.

Chavda V, Luo G, Bezbaruah R, Kalita T, Sarma A, Deka G Exploration (Beijing). 2024; 4(5):20230139.

PMID: 39439498 PMC: 11491308. DOI: 10.1002/EXP.20230139.

Cell Membrane-Coated Nanoparticles for Dental, Oral, and Craniofacial Diseases.

Wang K, Li Z, Zhou K, Liu B, Rao L, Bu L Research (Wash D C). 2024; 7:0478.

PMID: 39296987 PMC: 11409001. DOI: 10.34133/research.0478.

Navigating Antibacterial Frontiers: A Panoramic Exploration of Antibacterial Landscapes, Resistance Mechanisms, and Emerging Therapeutic Strategies.

Ralhan K, Iyer K, Diaz L, Bird R, Maind A, Zhou Q ACS Infect Dis. 2024; 10(5):1483-1519.

PMID: 38691668 PMC: 11091902. DOI: 10.1021/acsinfecdis.4c00115.

Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.

Huang Y, Guo X, Wu Y, Chen X, Feng L, Xie N Signal Transduct Target Ther. 2024; 9(1):34.

PMID: 38378653 PMC: 10879169. DOI: 10.1038/s41392-024-01745-z.

Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective.

Li M, Guo Q, Zhong C, Zhang Z Drug Deliv. 2023; 30(1):2288797.

PMID: 38069500 PMC: 10987056. DOI: 10.1080/10717544.2023.2288797.

References

Goldblatt D . Conjugate vaccines. Clin Exp Immunol. 2000; 119(1):1-3. PMC: 1905528. DOI: 10.1046/j.1365-2249.2000.01109.x. View

Zinkernagel R . On natural and artificial vaccinations. Annu Rev Immunol. 2002; 21:515-46. DOI: 10.1146/annurev.immunol.21.120601.141045. View

Plotkin S . Vaccines, vaccination, and vaccinology. J Infect Dis. 2003; 187(9):1349-59. DOI: 10.1086/374419. View

Emerich D, Thanos C . Nanotechnology and medicine. Expert Opin Biol Ther. 2003; 3(4):655-63. DOI: 10.1517/14712598.3.4.655. View

Metz B, Kersten G, Hoogerhout P, Brugghe H, Timmermans H, de Jong A . Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J Biol Chem. 2003; 279(8):6235-43. DOI: 10.1074/jbc.M310752200. View

Mann J, Scales H, Shakir E, Alexander J, Carter K, Mullen A . Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods. 2006; 38(2):90-5. DOI: 10.1016/j.ymeth.2005.11.002. View

Kyaw M, Lynfield R, Schaffner W, Craig A, Hadler J, Reingold A . Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006; 354(14):1455-63. DOI: 10.1056/NEJMoa051642. View

Couvreur P, Vauthier C . Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006; 23(7):1417-50. DOI: 10.1007/s11095-006-0284-8. View

Elamanchili P, Lutsiak C, Hamdy S, Diwan M, Samuel J . "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J Immunother. 2007; 30(4):378-95. DOI: 10.1097/CJI.0b013e31802cf3e3. View

10.

Reddy S, van der Vlies A, Simeoni E, Angeli V, Randolph G, ONeil C . Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007; 25(10):1159-64. DOI: 10.1038/nbt1332. View

11.

Andre F, Booy R, Bock H, Clemens J, Datta S, John T . Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008; 86(2):140-6. PMC: 2647387. DOI: 10.2471/blt.07.040089. View

12.

Gordon R, Lowy F . Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008; 46 Suppl 5:S350-9. PMC: 2474459. DOI: 10.1086/533591. View

13.

Jones R, Liu Y, Rigsby P, Sesardic D . An improved method for development of toxoid vaccines and antitoxins. J Immunol Methods. 2008; 337(1):42-8. DOI: 10.1016/j.jim.2008.05.009. View

14.

Dobrovolskaia M, McNeil S . Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2008; 2(8):469-78. DOI: 10.1038/nnano.2007.223. View

15.

Ishii Y, Nakae T, Sakamoto F, Matsuo K, Matsuo K, Quan Y . A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. J Control Release. 2008; 131(2):113-20. PMC: 7114651. DOI: 10.1016/j.jconrel.2008.07.025. View

16.

Kickhoefer V, Han M, Raval-Fernandes S, Poderycki M, Moniz R, Vaccari D . Targeting vault nanoparticles to specific cell surface receptors. ACS Nano. 2009; 3(1):27-36. PMC: 2641028. DOI: 10.1021/nn800638x. View

17.

Mendoza N, Ravanfar P, Satyaprakash A, Satyaprakah A, Pillai S, Creed R . Existing antibacterial vaccines. Dermatol Ther. 2009; 22(2):129-42. DOI: 10.1111/j.1529-8019.2009.01225.x. View

18.

Champion C, Kickhoefer V, Liu G, Moniz R, Freed A, Bergmann L . A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One. 2009; 4(4):e5409. PMC: 2671841. DOI: 10.1371/journal.pone.0005409. View

19.

Rudra J, Tian Y, Jung J, Collier J . A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A. 2010; 107(2):622-7. PMC: 2818904. DOI: 10.1073/pnas.0912124107. View

20.

Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T . Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater. 2010; 9(7):572-8. DOI: 10.1038/nmat2784. View